Document is current
Any future updates will be listed below
-
Authors
Atreya, Mihir R.
Cvijanovich, Natalie Z.
Fitzgerald, Julie C.
Weiss, Scott L.
Bigham, Michael T.
Jain, Parag N.
Schwarz, Adam J.
Lutfi, Riad
Nowak, Jeffrey
Allen, Geoffrey L.
Thomas, Neal J.
Grunwell, Jocelyn R.
Baines, Torrey
Quasney, Michael
Haileselassie, Bereketeab
Alder, Matthew N.
Goldstein, Stuart L.
Stanski, Natalja L.
-
Funding
Funding for this research was provided by:
Cincinnati Children's Research Foundation, Procter K-to-R Scholar Award
NIGMS (R35 GM126943)
National Institutes of Health (KL2TR001426)
- License Information
-
More Information
Article History
Received: 10 May 2023
Accepted: 28 June 2023
First Online: 3 July 2023
Declarations
:
: The study protocol was approved by Institutional Review Boards (IRBs) of the primary site (Cincinnati Children’s Hospital IR, Genomic Analysis of Pediatric Systemic Inflammatory Syndrome, IRB ID: 2008-0558) as well as all participating institutions. Informed consent was obtained from parent or guardian of patients. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional review boards of participating institutions and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
: M.R.A, N.L.S, and Cincinnati Children’s Hospital Medical Center (CCHMC) hold a provisional patent for the work detailed in this manuscript. M.R.A and Cincinnati Children’s Hospital (CCHMC) hold a provisional patent for a unified biomarker model—PERSEVERENCE that incorporates PERSEVERE and endothelial dysfunction markers to predict risk of multiple organ dysfunctions in sepsis. N.L.S and CCHMC hold a provisional patent for the use of PERSEVERE biomarkers in sepsis-associated acute kidney injury.
